Market Mover: Autolus (AUTL) Climbs at Midday June 23

Equities Staff  |

Today Autolus Therapeutics plc - ADR (NASDAQ: AUTL) is trading 10.17% up.

The latest price, as of 11:46:19 est, was $2.60. Autolus has moved $0.24 in trading today.

75,139 shares have exchanged hands.

As of the previous close, Autolus has a YTD change of 54.53%. The company is set to release earnings on 2022-08-04.

For technical charts, analysis, and more on Autolus visit the company profile.

About Autolus Therapeutics plc - ADR

Autolus Therapeutics plcis a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.

To get more information on Autolus Therapeutics plc - ADR and to follow the company's latest updates, you can visit the company's profile page here: Autolus Therapeutics plc - ADR's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content